Melinda Taschetta-Millane, Editorial Director
Melinda Taschetta-Millane, Editorial Director
Blog | Melinda Taschetta-Millane, Editorial Director | Women's Health | October 03, 2017

The Role of Personalized Breast Cancer Screening

The Role of Personalized Breast Cancer Screening

It is once again October, Breast Cancer Awareness Month. The American Cancer Society (ACS) estimates that about 252,710 new cases of invasive breast cancer and 63,410 new cases of carcinoma in situ (CIS) will be diagnosed in 2017. About 40,610 women will die from breast cancer this year.

Only lung cancer beats out breast cancer in women for the leading cause of cancer deaths, and the chance that a woman will die from breast cancer is about 1 in 37, or about 2.7 percent, according to the ACS. Since 2007, breast cancer death rates have been steady in women younger than 50, but have continued to decrease in older women. These decreases are attributed to the result of earlier and better screening procedures and treatments.

Having the topic of breast density in the limelight has also helped to raise awareness, and as of this month, and thanks to many, many hours of dedicated work from industry lobbyists, 30 states now require some level of patient density notification, according to densebreast-info.org.

Monica Saini, M.D., medical director — ABUS at GE Healthcare, says it’s an exciting time to be a breast radiologist “because we no longer have to prescribe to a one-size-fits-all screening exam,” she said in the itnTV video “Innovative Breast Cancer Screening for Women with Dense Breast Tissue.” In it, she discusses the advancements for women in personalized breast care, and how automated breast ultrasound (ABUS) helps meet the challenges of screening and diagnostic imaging of dense breast tissue.

“Instead of prescribing to this system, we can use a multimodality approach to individualize each woman’s breast care,” she explained, stating that the industry now has new tools, like risk assessment, and knows to look at the personal history of each patient, her family history of cancer and her personal biology, which is best demonstrated by breast density. “Using these tools together, we can come up with an individualized plan for each patient. We start with the gold standard of screening mammography.

“Now we have new advancements in technology with tomosynthesis that allows us to reduce the callback rate,” she continued. “But we have even newer technologies like automated breast ultrasound which allow us to screen dense breasted patients, which is about 40 percent of the population. When we use these tools together, we have a synergistic type of effect. So the magic is we find more cancer. And that’s the ultimate goal for a breast radiologist is to increase our cancer detection rate but decrease our false positives. New technology has given us game-changing applications that can be applied to breast imaging.”

You can watch the full video with Saini at http://bit.ly/2jI6KF2. In this issue, ITN is premiering its automated breast ultrasound systems comparison chart. You can review the system specs from participating companies on page 47
of this issue.

Related Content

Mammograms of a 49-year-old woman with invasive lobular carcinoma on the right-side breast

Mammograms of a 49-year-old woman with invasive lobular carcinoma on the right-side breast. A small mass with micro-calcifications on the right-side breast was detected correctly by AI with an abnormality score of 96%. This case was recalled by 7 out of 14 radiologists (4 breast radiologists and 3 general radiologists) initially (without AI) and all 14 radiologists recalled this case correctly with the assistance of AI.

News | Artificial Intelligence | February 11, 2020
February 11, 2020 — A new study, published in...
Sponsored Content | Videos | Artificial Intelligence | February 06, 2020
ProFound AI is an FDA-cleared artificial intelligence (AI) system for reading 3-D breast tomosynthesis images.
Feature | Breast Imaging | February 03, 2020 | By Barbara Smith
Women in the United States have a 1 in 8 (or about 13 percent) lifetime risk of being diagnosed with breast cancer du
ringing the cancer bell can do more harm than good, says an ASTRO study

Image courtesy of ASTRO

News | Radiation Oncology | January 27, 2020
January 27, 2020 — It's a scene that some cancer patients dream about: they celebrate the end of a course of radiatio
A 50-y-old postmenopausal woman with fibroadenoma (arrows) in left breast

A 50-y-old postmenopausal woman with fibroadenoma (arrows) in left breast. (A) Unenhanced fat-saturated T1-weighted MRI shows extreme amount of FGT (ACR d). (B) Moderate BPE is seen on dynamic contrast-enhanced MRI at 90 s. (C) Mean ADC of breast parenchyma of contralateral breast on diffusion-weighted imaging with ADC mapping is 1.5 × 10?3 mm2/s. (D) On 18F-FDG PET/CT, lesion is not 18F-FDG-avid, and BPU of normal breast parenchyma is relatively high, with SUVmax of 3.2. Photo courtesy of K Pinker, et al., Medical University of Vienna, Vienna, Austria

News | PET-MRI | January 27, 2020
January 27, 2020 — Researchers have identified several potentially useful...
Sponsored Content | Videos | Mammography | January 24, 2020
Imaging Technology News Contributing Editor Greg Freiherr interviewed...
Virtual reality during chemotherapy has been shown to improve breast cancer patients’ quality of life during the most stressful treatments
News | Virtual and Augmented Reality | January 21, 2020
January 21, 2020 — Virtual reality during chemotherapy has been shown to improve...
This is a lung X-ray reviewed automatically by artificial intelligence (AI) to identify a collapsed lung (pneumothorax) in the color coded area. This AI app from Lunit is awaiting final FDA review and in planned to be integrated into several vendors' mobile digital radiography (DR) systems. Fujifilm showed this software integrated as a work-in-progress into its mobile X-ray system at RSNA 2019. GE Healthcare has its own version of this software for its mobile r=ray systems that gained FDA in 2019.   #RSNA #

This is a lung X-ray reviewed automatically by artificial intelligence (AI) to identify a collapsed lung (pneumothorax) in the color coded area. This AI app from Lunit is awaiting final FDA review and in planned to be integrated into several vendors' mobile digital radiography (DR) systems. Fujifilm showed this software integrated as a work-in-progress into its mobile X-ray system at RSNA 2019. GE Healthcare has its own version of this software for its mobile r=ray systems that gained FDA in 2019.

Feature | RSNA | January 20, 2020 | Dave Fornell, Editor
Here are images of some of the newest new medical imaging technologies displayed on the expo floor at the ...
The study found that DBN laws helped some women understand they had increased breast density, but not that breast density is associated with a higher risk of breast cancer or that dense breasts limit the ability of mammograms to detect cancer
News | Breast Density | January 09, 2020
January 9, 2020 — A new study suggests that state-mandated notifications on...